Topic
Leukemic Blast Count
About: Leukemic Blast Count is a research topic. Over the lifetime, 3 publications have been published within this topic receiving 6 citations.
Papers
TL;DR: The blast reduction rate, which is not affected by the initial blast level, could be a factor with comparable prognostic value and was significantly higher in prednisone responders with respect to non responders.
4 citations
TL;DR: A biological model was devised that allowed us to distinguish non-cycling AML cells from cycling AML progenitors in human FLT3-ITD positive AML samples and assessed the impact of a potent FLT 3-directed inhibitor, TKI258 (Novartis), on leukemic cell expansion and the viability of non-Cycling cells.
2 citations
TL;DR: The overall prognosis in children with MDS is almost the same as in adults, with a median survival time of 19 months, and there are no well-established therapy strategies in MDS.
Abstract: Myelodysplastic syndromes (MDS) are heterogeneous diseases with cytopenia in the peripheral blood, dysplasia of two or three cell lines, and a low leukemic blast count in the bone marrow and peripheral blood. The syndrome is rare in childhood (1%-2% of all acute leukemias). In the advanced subtypes of MDS with 5% to 30% of blasts the risk of progression into acute leukemia is high, especially in childhood. Cytogenetic abnormalities like monosomy 7 are typical for children with MDS, and probably are an unfavourable prognostic factor. The overall prognosis is almost the same as in adults, with a median survival time of 19 months. There are no well-established therapy strategies in MDS. Intensive chemotherapy may be beneficial, at least in children and young adults, but the decision when to start treatment is difficult. At present allogeneic bone marrow transplantation is the only curative therapy available for MDS.
1 citations
Related Topics (5)
Performance Metrics
| Year | Papers |
|---|---|
| 2009 | 1 |
| 2005 | 1 |
| 1987 | 1 |